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Quantitative Gadolinium-Free 
Cardiac Fibrosis Imaging in End 
Stage Renal Disease Patients 
Reveals A Longitudinal Correlation 
with Structural and Functional 
Decline
Tori A. Stromp1,2, Tyler J. Spear3, Rebecca M. Holtkamp3, Kristin N. Andres4, 
Joshua C. Kaine4,5, Wissam H. Alghuraibawi6, Steve W. Leung  5, Brandon K. Fornwalt7 & 
Moriel H. Vandsburger6
Patients with end stage renal disease (ESRD) suffer high mortality from arrhythmias linked to fibrosis, 
but are contraindicated to late gadolinium enhancement magnetic resonance imaging (MRI). We 
present a quantitative method for gadolinium-free cardiac fibrosis imaging using magnetization 
transfer (MT) weighted MRI, and probe correlations with widely used surrogate markers including 
cardiac structure and contractile function in patients with ESRD. In a sub-group of patients who 
returned for follow-up imaging after one year, we examine the correlation between changes in fibrosis 
and ventricular structure/function. Quantification of changes in MT revealed significantly greater 
fibrotic burden in patients with ESRD compared to a healthy age matched control cohort. Ventricular 
mechanics, including circumferential strain and diastolic strain rate were unchanged in patients with 
ESRD. No correlation was observed between fibrotic burden and concomitant measures of either 
circumferential or longitudinal strains or strain rates. However, among patients who returned for 
follow up examination a strong correlation existed between initial fibrotic burden and subsequent loss 
of contractile function. Gadolinium-free myocardial fibrosis imaging in patients with ESRD revealed a 
complex and longitudinal, not contemporary, association between fibrosis and ventricular contractile 
function.
Sudden cardiac death and fatal arrhythmias are leading causes of mortality for patients on routine hemodialysis 
for end stage renal disease (ESRD)1. Increasing evidence suggests a link between left ventricular (LV) hyper-
trophy2,3 and/or fibrosis4–6 to fatal arrhythmias and heightened mortality rates in patients with ESRD. While 
cardiac magnetic resonance imaging (CMR) with gadolinium contrast agents is the clinical standard for fibrosis 
imaging7–9, gadolinium agents are contraindicated in patients with ESRD10. In place of direct measurement of 
tissue fibrosis, measurements of both ventricular structure (LV hypertrophy) and mechanical function including 
reduced global longitudinal strain (GLS) and diastolic strain rate are used in patients with ESRD11. Consequently, 
investigations into molecular mechanisms of cardiac fibrosis, the role of fibrosis in promoting adverse outcomes, 
and potential longitudinal treatments in ESRD all rely on either repeated invasive biopsies or surrogate measures 
of fibrosis.
1Department of Physiology, University of Kentucky, Lexington, KY, USA. 2Glaxo Smith Kline Research and 
Development, Philadelphia, PA, USA. 3Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, 
USA. 4College of Medicine, University of Kentucky, Lexington, KY, USA. 5Gill Heart and Vascular Institute, University 
of Kentucky, Lexington, KY, USA. 6Department of Bioengineering, University of California Berkeley, Berkeley, CA, 
USA. 7Department of Imaging Science and Innovation, Geisinger, Danville, PA, USA. Correspondence and requests 
for materials should be addressed to M.H.V. (email: moriel@berkeley.edu)
Received: 9 August 2018
Accepted: 5 November 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIentIfIC REPoRTS |         (2018) 8:16972  | DOI:10.1038/s41598-018-35394-4
In a prior cardiac magnetic resonance imaging study we demonstrated a gadolinium-free approach to identify 
cardiac fibrosis based on changes in magnetization transfer (MT) weighting on cine balanced steady state free 
precession (bSSFP) images12. In patients referred for diagnostic imaging with gadolinium, the normalized signal 
difference between pairs of differentially MT-weighted bSSFP images (ΔS/So) correlated with the severity of 
fibrosis when assessed using gadolinium based techniques as a standard12. In the current study we expand this 
method for whole heart quantitative fibrosis imaging in patients with ESRD without bone mineral density loss 
over one year. We present a method by which to measure global fibrotic burden based on changes in the distribu-
tion of ΔS/So values, termed divergence. We probe correlations between fibrotic burden and ventricular hyper-
trophy or cardiac mechanics. Finally, in a sub-group of patients who returned for follow-up imaging after 1 year 
we demonstrate quantitative changes in fibrotic burden and examine correlations with changes in left ventricular 
structure and function.
Results
Patients with ESRD were recruited from within an ongoing study at our institution13. Demographics for patients 
with ESRD (n = 29) and healthy controls (n = 33) are detailed in Table 1. Groups were well matched in age and 
gender. Patients with ESRD had larger body mass index than controls (p < 0.001). Hemodialysis vintage in 
patients with ESRD was 4.8 [2.1, 7.7] years. Six patients had prior failed kidney transplants. Clinical features of 
patients with ESRD are summarized in Table 2. Twenty three participants from the original study were eligible to 
complete follow-up within the study period of September 2015-April 2017. Participants who did not return had 
discontinued dialysis following kidney transplant (n = 2), refused for medical or personal reasons (n = 6), were 
deceased (n = 2), or were lost to follow-up (n = 3). A total of 11 participants (Supplemental Table 1) completed 
the follow-up exam at 12.2 ± 0.5 months after baseline (range 10.9–12.7 months).
Imaging of Cardiac Fibrosis. Representative MT-weighted CMR maps from a patient with ESRD (Fig. 1) 
demonstrate diffusely elevated ΔS/So values, particularly in the septum and towards the base of the left ventricle. 
The color scheme for presentation of ΔS/So maps was previously chosen to emulate late gadolinium enhance-
ment, with healthy myocardium appearing dark and densely fibrotic and edematous myocardium appearing 
bright white12. The complete data from a representative healthy control is shown in Supplemental Fig. 1 and 
demonstrates uniformly normal values throughout the myocardium. Mean global ΔS/So values were signifi-
cantly higher in ESRD (145 ± 17%) compared to controls (130 ± 12%, p < 0.001, Fig. S2). We observed all three 
prevailing patterns of cardiac fibrosis in patients with ESRD including thin scar, diffuse global fibrosis, and focal 
reactive fibrosis at the ventricular insertion point (Fig. S3). In order to quantify overall changes in fibrotic burden, 
a standard cumulative distribution of ΔS/So values was defined by combining all myocardial ΔS/So values from 
all healthy participants (Fig. 2). For each individual examined, the standard cumulative distribution was dynam-
ically resized to account for differences in heart size and to match the number of voxels per heart. The individual 
cumulative distribution function of ΔS/So values was then compared against the appropriately-sized standard 
distribution, and the difference between cumulative distributions was integrated across ΔS/So values as shown in 
Fig. 2. The resulting value was used as a quantitative marker of fibrosis, termed divergence (Fig. 2). A rightward 
shift is detected when voxels demonstrate increased ΔS/So values, consistent with increased extracellular volume 
Variable
Healthy Controls
(n = 33)
ESRD
(n = 29)
Demographics
   Age (yrs.) 54.0 ± 10.9 53.7 ± 12.8
   Male 15 (45) 14 (48)
   White/Caucasian 29 (88) 16 (55)
   Black/African American 1 (3) 12 (41)
   Asian 0 1 (3)
   American Indian 1 (3) 0
   Hispanic 2 (6) 0
   Body Mass Index (kg/m2) 24.2 ± 2.3 31.6 ± 6.8†
Cardiac Structure and Function
   Left Ventricular Mass Index (g/m2) 60.4 ± 13.3 94.3 ± 27.8†
   Mass:Volume Ratio 1.2 [1.0, 1.5] 1.6 [1.3, 2.0]†
   Septal Thickness (cm) 0.9 ± 0.2 1.3 ± 0.03†
   End Systolic Volume (mL) 34.5 [25.3, 46.0] 36.5 [31.5,54.4]
   End Diastolic Volume (mL) 92.3 ± 25.3 116.5 ± 41.0*
   Ejection Fraction (%) 60.5 [56.0, 64.4] 63.8 [58.4, 68.1]
   Heart Rate (bpm) 60.8 ± 8.8 72.3 ± 10.8†
   QRS Duration (ms) 90.0 [84.0, 98.0] 94.0 [77.0, 104.0]
   QTc interval (ms) 422.7 ± 18.4 463.0 ± 37.7†
Table 1. Participant Characteristics. Continuous variables presented as mean ± standard deviation or median 
[interquartile range]. Categorical variables presented as count (%).*p < 0.01, †p < 0.001.
www.nature.com/scientificreports/
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fraction12. Divergence was significantly higher in patients with ESRD (16.3 ± 14.3 AU ESRD vs. 6.5 ± 5.7 AU 
Control, p = 0.003, Fig. S2), but did not correlate with hemodialysis vintage (ρ = −0.16, p = 0.395).
Among patients who returned for follow-up imaging, the mean ventricular ΔS/So values (144.8 ± 19.2% 
Baseline, 150.0 ± 20.1% Follow Up, p = 0.55) and divergence values (16.9 ± 17.1% Baseline, 20.9 ± 15.3% Follow 
Up, p = 0.57) did not change substantially from baseline measurements. However, significant heterogeneity was 
observed between individuals. Specifically, four individuals demonstrated moderate increases in ΔS/So across 
a large spatial area that are consistent with increased diffuse fibrosis (Fig. S4), three individuals demonstrated 
abrupt and substantial increases in regional ΔS/So values consistent with focal fibrosis (Fig. 3), and 4 individuals 
showed minimal changes in ΔS/So values between imaging time points (Fig. S5). A trend of inverse correlation 
between initial divergence values and subsequent change in divergence over 1 year (ρ = −0.47, p = 0.14) was 
observed, wherein individuals with initially high divergence values showed little change over one year, and those 
with low initial divergences demonstrated greater increases over the same period.
Cardiac Structure, Function, and Mechanics. Ejection fraction was similar between groups (Table 1). 
Patients with ESRD had increased LVMI and mass to volume ratio (Table 1), with 69% of patients demonstrat-
ing values consistent with ventricular hypertrophy. While global circumferential diastolic strain rate was similar 
between the ESRD and healthy control groups (Fig. 4A), global longitudinal strain was reduced in ESRD (Fig. 4B). 
Notably, mid-ventricular circumferential diastolic strain rate was unchanged in ESRD (158 ± 51%/s) compared 
to controls (158 ± 3%/s, p = 0.657). Parameters of cardiac structure and global function (Table S2), chronotropic 
parameters (Table S2), and both systolic and diastolic strains and strain rates (Table S3) were unchanged after one 
year among the patients with ESRD who returned for follow-up examination. Only longitudinal diastolic strain 
rate demonstrated a trend towards decreased magnitude after one year (p = 0.11).
Cardiac Mechanics and Fibrosis are longitudinally, not concomitantly correlated. No correla-
tion was observed between divergence and either concomitant diastolic strain rate (ρ = 0.06, p = 0.646) or GLS 
(ρ = 0.02, p = 0.910, Fig. 5). A moderate correlation was evident when comparing heightened divergence with 
increased LVMI (ρ = 0.31, p = 0.014, Fig. 5) and septal thickness (ρ = 0.27, p = 0.035). However, many patients 
with ESRD and significantly elevated LVMI demonstrated normal divergence values (Fig. 5A). This relationship is 
further illustrated in Fig. 6 by comparison of heterogeneously elevated ΔS/So patterns in 4 patients with increased 
septal thickness and heightened LVMI (a larger subset are shown in Fig. S6). In contrast, increased LVMI was sig-
nificantly correlated with reduced diastolic strain rate (ρ = −0.26, p = 0.043) and attenuated global longitudinal 
strain (ρ = 0.38, p = 0.002) across participants.
Among patients who returned for follow-up examination, initial divergence values were not correlated with 
corresponding measures of LVMI (ρ = 0.03, p = 0.92), mass to volume ratio (ρ = 0.16, p = 0.62), global longitudi-
nal strain (ρ = −0.04, p = 0.91), circumferential diastolic strain rate (ρ = 0.37, p = 0.27), or longitudinal diastolic 
strain rate (ρ = 0.09, p = 0.79). While the correlations between divergence and LVMI (ρ = 0.55, p = 0.08), mass to 
volume ratio (ρ = 0.18, p = 0.60), global longitudinal strain (ρ = 0.52, p = 0.10), and both circumferential diastolic 
strain rate (ρ = 0.39, p = 0.23) and longitudinal diastolic strain rate (ρ = 0.42, p = 0.19) were greater after one year, 
all failed to reach statistical significance in a small sample size.
Although divergence and ventricular structure/mechanics were not concomitantly correlated, there was a 
significant correlation between initial divergence values and corresponding changes in both circumferential 
and longitudinal diastolic strain rates over one year (Table 3 and Fig. 7). A similar trend was observed with 
respect to changes in global longitudinal strain, but failed to reach statistical significance (Table 3). Interestingly, 
when examining changes in divergence between examinations, only the initial magnitude of global longitudinal 
strain correlated with subsequent changes in divergence (Table 3 and Fig. 7). In addition, individual changes in 
divergence between visits were not correlated with corresponding changes in LVMI (ρ = 0.43, p = 0.26), GLS 
Clinical Features Results
Dialysis Duration (years) 4.8 ± 3.2
Primary Etiology of End Stage Renal Disease
   Diabetes 12 (41)
   Hypertension 7 (24)
   Glomerulonephritis 2 (7)
   Reflux Nephropathy 2 (7)
   Obstructive Nephropathy 1 (3)
   Interstitial Nephritis 1 (3)
   Focal Segmental Glomerulosclerosis 1 (3)
   Unknown 3 (10)
Comorbidities
   Hypertension 27 (93)
  Diabetes 17 (59)
   Prior Myocardial Infarction 4 (14)
Table 2. Clinical Features of Patients with ESRD. Continuous variable presented as mean ± standard deviation. 
Categorical variables presented as count (%).
www.nature.com/scientificreports/
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(ρ = 0.41, p = 0.21) and circumferential diastolic strain rate (ρ = 0.39, p = 0.24). A strong trend was observed 
between changes in divergence and corresponding changes in longitudinal diastolic strain rate between examina-
tions (ρ = −0.58, p = 0.0595). However, individual changes in LVMI were significantly correlated with concom-
itant reductions in GLS (ρ = 0.62, p = 0.043) and circumferential diastolic strain rate (ρ = −0.76, p = 0.007) as 
shown in Fig. 8. Changes in LVMI and longitudinal diastolic strain rate demonstrated a trend towards correlation 
(ρ = −0.52, p = 0.099).
Discussion
Nearly 40% of mortality among patients with ESRD is attributed to arrhythmias and sudden cardiac death1. Prior 
studies using excised tissue3,6 and CMR with gadolinium4,14 established cardiac fibrosis as a potential substrate of 
arrhythmia and sudden death in ESRD15. With contraindications to gadolinium in place, ventricular hypertro-
phy and cardiac mechanics are often used as surrogate imaging markers of cardiac fibrosis, and are also targets 
for pharmacological reversal in ESRD16–18. In this study we used an MT-weighted CMR technique to quantify 
global ventricular extracellular matrix expansion in patients with ESRD. While we found that patients with ESRD 
with heightened fibrosis often demonstrate ventricular hypertrophy and attenuated longitudinal and diastolic 
contractile function, such structural and mechanical measurements were often similarly altered in patients with-
out fibrosis. Additionally, while fibrotic burden was not concomitantly correlated with either ventricular hyper-
trophy or attenuated mechanical function, greater divergence values at initial examination correlated strongly 
Figure 1. Representative ΔS/So maps from an ESRD patient. (A–H) ΔS/So maps from the left ventricular 
base towards the apex in a patient with ESRD demonstrate a gradient of elevated ΔS/So across slice positions. 
Elevated values consistent with dense scar appear in the septal mid-wall at the base of the left ventricle (A–C). 
At the mid-ventricle (D,E) ΔS/So values are consistent with diffuse fibrosis in the septum and normal tissue 
in the free wall. Towards the apex (G,H) ΔS/So values are consistent with healthy tissue throughout the 
myocardium. (I) The corresponding bulls-eye plot illustrates patterns of elevated mean ΔS/So, particularly in 
septal segments. Global mean ΔS/So was 170% and divergence was 37.0 AU.
www.nature.com/scientificreports/
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with subsequent reductions in diastolic strain rates over one year. Further, attenuated initial global longitudinal 
strain correlated strongly with subsequent increases in fibrotic burden over the same period. Importantly, overall 
changes in longitudinal diastolic strain rates were highly correlated to changes in LVMI and closely mirrored by 
changes in fibrotic burden. Together, these findings highlight the complex interplay between global structural and 
functional changes and local changes in myocardial fibrotic burden in the setting of ESRD.
Late gadolinium enhancement is a standard for identification of myocardial scar and for quantification of scar 
distribution and burden. Before consensus that patients with ESRD should not undergo late gadolinium enhance-
ment imaging, Schietinger et al.4 used gadolinium contrast agents to identify three prevailing enhancement 
Figure 2. MT-weighted CMR for Tissue Characterization. End diastolic cine bSSFP images acquired with 
a 45° excitation flip angle in a (A) representative healthy control and (E) patient with ESRD are paired with 
images acquired at excitation flip angle of 5° (B and F, respectively). (C,G) Maps of ΔS/So are generated as 
ΔS/So = (S45 − S5)/S5 * 100 (%). (C) ΔS/So maps from healthy controls demonstrate low and uniform ΔS/So 
values. (G) Elevations in ΔS/So observed in patients with ESRD are consistent with those seen in fibrotic tissue 
(see12). (D,H) Segmental average ΔS/So values from LV base (outer ring) to apex (inner ring) are represented 
using a bullseye plot. Compared to uniformly low ΔS/So values of a healthy control (D), ΔS/So demonstrates 
regional heterogeneity in a patient with ESRD, with elevated values primarily in the septum (H). (I) Using all 
LV myocardial ΔS/So values from the control group, a standard cumulative distribution function was generated 
for this study (black curve). The simulated ΔS/So distribution was dynamically resized to match the number 
of voxels per individual LV and compared to the distribution of ΔS/So values for that individual. Cumulative 
distributions from the representative healthy control (orange) and ESRD patient (red) are shown. The area 
between the simulated and participant’s observed distribution represents the global shift in ΔS/So values and 
is termed divergence. Measurement of divergence integrates the presence of diffuse elevations caused by tissue 
fibrosis over the entire LV.
Figure 3. Focal fibrosis development. (A–C) Images acquired in a 42 year old female patient on hemodialysis 
for approximately two years with plural effusion demonstrate minor signal elevations but (D) low average ΔS/So  
across the left ventricle. (E–H) While global divergence increased by only 8.7 AU at follow-up, regional 
elevations are evident at the basal and mid ventricular septum. The elevated values are consistent with scar 
tissue as observed in Stromp et al.12. Imaging of the same basal/mid-ventricular slice (B,E) highlights the ability 
to detect the development of mid-wall enhancement between visits.
www.nature.com/scientificreports/
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patterns in patients with ESRD including thin scar from prior myocardial infarction, diffuse enhancement, and 
focal fibrosis at a right ventricular insertion point. Similarly, Mark et al. observed patterns of thin scar or diffuse 
enhancement through various regions of the left ventricle in most patients with ESRD5. Our previous validation 
of MT-weighted CMR revealed a strong correlation between elevated ΔS/So values and late gadolinium enhance-
ment tissue status12, and in this study we observed patterns of elevated ΔS/So similar to the three prevailing 
patterns described by Schietinger and colleagues (Fig. S3). Among these patterns, diffuse and heterogeneous 
enhancement of the LV was most common. When regionally diffuse elevations of ΔS/So occur concurrently with 
ventricular hypertrophy, calculation of a global mean ΔS/So value is more likely to obscure potentially meaning-
ful elevations. Given prevailing histological evidence of diffuse cardiac fibrosis in ESRD, we chose to compare 
cumulative distributions of ΔS/So for each individual against a standard healthy distribution as a mechanism to 
integrate small elevations in ΔS/So that are scattered throughout the left ventricle while simultaneously normaliz-
ing for differences in LV mass (Fig. 2). This approach enables quantitation of a spatially diffuse and heterogeneous 
process and enabled longitudinal comparison of global ventricular fibrotic burden without the need for biopsy.
Increased collagen content in fibrotic myocardium is associated with greater tissue stiffness, cardiomyocyte 
hypertrophy and reduced LV contractile function19. Subsequently, both hypertrophy and mechanical function 
are often used surrogate imaging markers of fibrosis in studies of patients with ESRD. Ventricular hypertrophy 
is highly prevalent among patients with ESRD (up to 80%) and associated with poorer prognosis5,17. In agree-
ment with prior studies5,20,21, we observed substantial hypertrophy in patients with ESRD, yet only a moder-
ate correlation was observed between simultaneous measurements of LVMI and divergence. Similarly, reduced 
global longitudinal strain in patients with ESRD has been demonstrated using both CMR22 and echocardiogra-
phy23–25. While we also observed reduced mean GLS in patients with ESRD compared to healthy controls, most 
values remained well within the normal variation of healthy cohorts11,26. Further, comparing divergence against 
simultaneous measurements of both GLS and circumferential diastolic strain rate failed to reveal meaningful 
associations, similar to reports in hypertrophic cardiomyopathy27. While ventricular fibrosis and reduced strain 
Figure 4. Patients with ESRD demonstrated preserved diastolic circumferential strain rate and reduced global 
longitudinal strain compared to controls. (A) Circumferential diastolic strain rate was similar between ESRD 
(162.8 ± 41.7%/sec) and control groups (174.1 ± 33.9%/sec, p = 0.247). (B) Peak global longitudinal strain (ELL) 
was attenuated in ESRD (−20.5 ± 4.1%) compared to controls (−22.9 ± 3.5%, p = 0.035). Gray bars indicate 
group means, *p < 0.05.
Figure 5. Association of divergence with structural and functional measurements. (A) Divergence was 
moderately correlated with LVMI (ρ = 0.31, p = 0.014), however, among severely hypertrophic individuals 
(LVMI >100 g/cm2) divergence was highly variable. (B) Neither diastolic strain rate (ρ = 0.06, p = 0.646) nor 
(C) global longitudinal strain (ρ = 0.02, p = 0.910) correlated with divergence.
www.nature.com/scientificreports/
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have been correlated in individuals without ESRD28–30, measurement of contractile function in ESRD is com-
plicated by hemodynamic fluctuations due to timing relative to hemodialysis23,24. Such fluctuations have been 
demonstrated to introduce sampling bias to the measurement of contractile function with echocardiography31,32. 
Figure 6. Various spatial patterns of elevated ΔS/So were observed among hypertrophic patients with ESRD. 
(A–D) Representative end diastolic images acquired using a 45° excitation flip angle at the mid-ventricle are 
shown for 4 hypertrophic patients with ESRD. (E–H) Corresponding ΔS/So maps reveal different patterns and 
magnitudes of ΔS/So elevation despite the common structural feature of hypertrophy. An expanded version of 
this figure including 12 patients can be found in the Supplemental Data.
Year 1
Δ Between Year 1 and Baseline
Left Ventricular Mass Index
(LVMI)
Diastolic Strain Rate
(DSR)
Global Longitudinal  
Strain
(GLS)
Longitudinal  
Diastolic Strain Rate
(LDSR) Divergence
Divergence 0.45 (0.17) −0.61 (0.047) 0.54 (0.089) −0.63 (0.039) −0.47 (0.14)
LVMI −0.35 (0.29) 0.27 (0.42) −0.55 (0.083) 0.70 (0.016) 0.53 (0.091)
MVR 0.42 (0.20) −0.18 (0.59) 0.22 (0.51) 0.35 (0.29) 0.27 (0.41)
DSR 0.10 (0.77) −0.50 (0.12) 0.01 (0.99) −0.28 (0.41) 0.48 (0.13)
GLS −0.35 (0.29) −0.17 (0.63) −0.11 (0.74) 0.11 (0.77) 0.61 (0.046)
LDSR 0.28 (0.41) 0.13 (0.70) 0.15 (0.65) 0.25 (0.45) −0.47 (0.15)
Table 3. Correlation between initial structure, function, and fibrosis and changes over 1 year. Data are 
presented as Pearson’s ρ and corresponding (p value). P < 0.05 was considered statistically significant. 
Significant correlations are in bold.
Figure 7. Baseline levels of fibrosis and global longitudinal strain correlated with corresponding parametric changes 
over one year. Patients with higher baseline divergence values demonstrated greater loss of (A) global longitudinal 
strain (ΔGLS) and (B) global longitudinal diastolic strain rate (ΔGLDSR) over one year. (C) Interestingly, there was 
also a correlation between attenuated global longitudinal strain at baseline and subsequent increases cardiac fibrosis 
over one year. Pearson’s correlation coefficients and statistical values can be found in Table 3.
www.nature.com/scientificreports/
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Further, reduced contractile function has not consistently correlated with either histological measures of fibrosis 
in the ESRD population32, or heart failure or mortality in patients with ESRD33. A distinct finding of this study is 
that the change in fibrotic burden over one year was variable among patients with ESRD but correlated with the 
degree of attenuation of GLS at the time of initial examination. While this may suggest that reduced contractile 
function promotes cardiac fibrosis, Hayer and colleagues recently reported that noticeable loss of GLS occurred 
over one year in 30 early-stage chronic kidney disease patients, despite preserved and normal left ventricular 
mass and extracellular volume11. Further, we observed that loss of contractile function was highly correlated to 
increases in ventricular mass. Together, these findings highlight the intrinsic difficulty of using discrete measure-
ments to assess whether and how tissue fibrosis, hypertrophy, and loss of contractile function are synergistic or 
merely concomitant pathological processes in the setting of ESRD.
Several limitations to our study should be noted. First, while MT-weighted imaging of cardiac fibrosis has 
previously been compared to late gadolinium enhancement, it has not been validated directly against histology in 
large animals or humans. This should be performed as part of further validation of fibrosis in the setting of kidney 
disease. Further, this study was performed at 1.5 T where the impact of B1 heterogeneity is modest when com-
pared to 3 T. Extension of this technique to 3 T scanners will likely require alternate MT-weighting methods, or 
restrictive analysis to the septum. In addition, since the initial goal of our study was to probe for tissue fibrosis in 
patients with ESRD we used healthy age matched adults as our control population. Second, acquisition of image 
pairs requires two consecutive breath holds. To mitigate the impact of potential motion, image registration was 
performed prior to calculation of ΔS/So. Third, age-related extracellular matrix expansion34 may have impacted 
both groups, unrelated to underlying ESRD status. Further, while reflecting proportions within the ESRD pop-
ulation1, group differences in race may have led to imbalanced risk factors and confounded measures of cardiac 
function2. An additional major limitation to this study is the small sample of patients who returned for follow up 
examination after one year. Among those who were eligible for follow up (alive and without kidney transplant) 
but did not participate in the second scan, many cited deteriorating overall health as a major barrier to participa-
tion. Subsequently, a recruitment bias towards healthier patients may have obscured correlations between fibrosis, 
structure, and function over time that would have been observed in a larger ESRD cohort. It is entirely possible 
that with a larger cohort we may have seen a strong trend towards universal fibrotic progression among patients 
with ESRD, or greater concomitant correlations. Further, we did not have the statistical power within this group 
to examine whether heterogeneity in progression of fibrosis was caused by differences in underlying demographic 
factors including hemodialysis vintage, comorbidities, or medical history. A larger sample size may have also 
revealed stronger correlations between initial strain values and subsequent changes. In addition, we did not have 
access to patient dialysis records and could neither control for, nor examine the potential impact of changes in 
fluid maintenance between visits.
Conclusions
We applied MT-weighted CMR and developed quantitative methods for myocardial tissue characterization in 
patients with ESRD. Comparing divergence with LVMI and global longitudinal strain by CMR confirms that the 
association between extracellular matrix remodeling, cardiomyocyte hypertrophy, and attenuated contractile func-
tion is complex. The ability to non-invasively derive all three measures from CMR can empower the study of heart 
failure, prognosis, and mortality in the setting of ESRD. Future studies could utilize this combination to examine 
the acute impacts of dialysis initiation, or to test specific biomarkers of fibrotic progression in the setting of ESRD.
Methods
Participants and Recruitment. Patients on routine hemodialysis for ESRD were prospectively referred 
from the University of Kentucky Healthcare Department of Nephrology if they had no arrhythmia nor CMR 
incompatible metal or devices (n = 33). Healthy volunteers without cardiovascular disease, hypertension, dia-
betes, obesity, tobacco use, or CMR incompatibilities were prospectively included if within the age range of our 
Figure 8. Hypertrophy correlated with attenuation in cardiac mechanics. (A) Increases in LVMI over one year 
strongly correlated with decreases in circumferential diastolic strain rate (r2 = 0.58, p = 0.007) and (B) with 
attenuation in global longitudinal strain (r2 = 0.38, p = 0.043).
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patients (n = 44). Voluntary informed consent was obtained prior to participation. Participants were excluded 
from data analysis if unable to hold their breath or complete the MRI protocol (n = 1 ESRD each). Body mass 
index >26 kg/m2 in healthy controls (n = 3), abnormal electrocardiogram (n = 1), discovery of aging related 
(n = 1) or congenital abnormalities (n = 1), or hardware failures discovered after imaging (n = 5) were additional 
grounds for exclusion. The protocol was approved by the University of Kentucky Institutional Review Board. All 
research was performed in accordance with relevant guidelines and regulations.
Cardiac MRI Protocol. A 12-lead electrocardiogram was conducted prior to MRI. Imaging occurred on 
non-dialysis days with a 1.5 T Siemens Aera scanner (Erlangen, Germany) using an 18-channel body matrix 
coil and 12-channel spine coil. MT-weighted CMR was completed as previously described12. During separate 
end expiratory breath holds, cine bSSFP image pairs were obtained using excitation flip angles of 5° and 45° in a 
short axis stack from LV base to apex. Parameters included TE: 1.2 ms, TR: 3.2 ms, bandwidth: 930 Hz, matrix: 
256 × 256, in-plane resolution: 1.02 × 1.02 mm, slice thickness: 8 mm, and GRAPPA 2.
Structure, Function and Strain Analysis. Ventricular volumes and mass were analyzed from short axis 
images in Argus Viewer (Siemens Healthcare, Erlangen, Germany). Circumferential and longitudinal strains 
were assessed via custom feature tracking algorithm35 (Fig. S7). Global longitudinal strain was measured from a 
4-chamber long axis cine image.
Quantification of ΔS/So Enhancement. Images were analyzed in MATLAB (2014a, The MathWorks 
Inc., Natick, MA). Cine image pairs with excitation flip angles of 45° (Fig. 1A and E) and 5° (Fig. 1B and F) 
were registered when necessary to align the LV myocardium. Maps of ΔS/So (Fig. 1C and G) were generated as 
described12 for each slice using the formula ΔS/So = (S45° − S5°)/S5° * 100 (%), where S is signal intensity per voxel. 
Figures are presented with a 2 × 3 median filter and color schemes that emulate late gadolinium enhancement 
images as described previously12. The LV myocardium was manually segmented and end diastolic unfiltered ΔS/So 
maps were used for quantitative analysis. Bullseye plots demonstrate mean ΔS/So per sector (Fig. 2D and H). 
Mean ΔS/So per individual was calculated from all myocardial voxels.
Statistical Analysis. Statistics were computed using SPSS Statistics (version 22, IBM Corp, Armonk, NY). 
Shapiro-Wilk and Levene’s tests assessed normality and homogeneity of variance. Student’s t-tests compared 
group means for heart rate, end diastolic volume, circumferential diastolic strain rate, and ΔS/So. Mann-Whitney 
U tests compared group body mass index, LVMI, mass:volume ratio, septal thickness, end systolic volume, ejec-
tion fraction, QRS duration, QTc interval, GLS, divergence, and serum biomarkers. Baseline and follow-up results 
were compared using related-samples Wilcoxon signed rank tests for EDV, ESV, and cardiac output. All other 
results were compared using analysis of variance (ANOVA) with repeated measures. Change in divergence across 
scans was compared against measures of structure and function using Pearson correlations. Associations of imag-
ing results with measures of structure, function, and serum biomarkers were measured by Pearson correlations. 
Data are presented as mean ± standard deviation, median [interquartile range], or count (%) where appropriate. 
P < 0.05 was considered significant.
Ethics approval. Voluntary informed consent was obtained prior to participation. The protocol was 
approved by the University of Kentucky Institutional Review Board.
Availability of Data
All data will be made available from the corresponding author upon reasonable request.
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